$Sarepta Therap(SRPT.US) | 𝐒𝐚𝐫𝐞𝐩𝐭𝐚: H.C. Wainwright reiterates 𝐒𝐞𝐥𝐥, maintains 𝐏𝐓 𝐚𝐭 $𝟓
Analyst sees rising efficacy risks from new Roche study, with limited upside and significant downside to core U.S. ELEVIDYS franchise.Source: Hardik Shah
Share your thoughtsWhat's on your mind?
0 / 2,000
- B
RXRX 一周展望，By Grok
$Recursion Pharmaceuticals(RXRX.US) Recursion Pharmaceuticals Inc.（RXRX）Weekly Report (2025.11.22-11.29) The extent of your achievements can largely be seen from how much pain you can endure...